Agoracom Blog Home

Posts Tagged ‘medical Marijuana’

END OF DAY ALERT: (TBP: CSE) UP 38% ON 4.3M SHARES TRADED!

Posted by AGORACOM-JC at 5:05 PM on Monday, February 13th, 2017

TRADING ALERT!!!

TBP: CSE UP 38% ON 4.3M SHARES TRADED!

Tbp large

Close: $0.79 Up: $0.22

Percentage: +38% Volume: 4.3M Shares

Hub On AGORACOM

PhytoPain Pharma Provides USA Regulatory Update for Its Cannabis Inhalation Product PPP001 $GCI.ca

Posted by AGORACOM-JC at 8:41 AM on Monday, September 26th, 2016

Growpros_hub_large

  • PPP had filed a RFD for PPP001 to be classified as a drug and assigned to the Center for Drug Evaluation and Research
  • RFD enables the FDA to determine the product type and appropriate lead center.

OTTAWA, ONTARIO–(Sept. 26, 2016) - PhytoPain Pharma (“PPP“), a subsidiary of GrowPros Cannabis Ventures Inc. (“GrowPros” or the “Company” or “GCI“) (CSE:GCI), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions, received an Acknowledgement Letter from the U.S. Food and Drug Administration (“FDA“) after submitting a Request for Designation (“RFD“). PPP had filed a RFD for PPP001 to be classified as a drug and assigned to the Center for Drug Evaluation and Research (“CDER“). The RFD enables the FDA to determine the product type and appropriate lead center. If the FDA has not issued a designation letter within 60 calendar days of the filing of the RFD, PPP’s recommendation will become the designated classification and assignment.

According to Dr. G. Chamberland, Chief Scientific Officer, the RFD was submitted to establish the lead review for the PPP001-kit. He stated, “PPP recommended that the product PPP001-kit (PPP001 drug component and PPP-titanium pipe device component) be regulated as a Combination Product and that based on the Primary Mode of Action (PMOA) that primary jurisdiction be granted to CDER.” Dr. Chamberland further commented that this regulatory filing is part of PPP’s dedication to the commercialization of marijuana as a prescription controlled drug and the corporation’s plan to seek reimbursement by insurers for patients.

About PPP001-kit product

PPP001-kit product will be prescribed by physicians and available in pharmacies as two separate products packaged together in a single package and is comprised of the prescription controlled drug PPP001 (dried standardized cannabis sativa in a blister pack) and the fully assembled device PPP001-titanium pipe. The titanium pipe will be used to generate the smoke by combustion to deliver the active ingredients via inhalation. The drug component and device component will be linked together by the labelling of each component. Each blister of PPP001 drug pellet contains cannabis sativa with a standardized amount of delta-9-tetrahydrocannibinol. A single PPP001 drug pellet is pushed out of the blister by the patient and inserted into the PPP-titanium pipe for combustion and inhalation of the smoke.

About RFD

An RFD is also referred to as an applicant’s letter of request to the FDA (see 21 Code of Federal Regulations (“CFR”) 3.2(j)). It is a written submission to the Office of Combination Products (“OCP”). RFDs generally request a determination of (1) the regulatory identity or classification of a product as a drug, device, biological product, or combination product, and/or (2) either the component of FDA that will regulate the product if it is a non-combination product, or which Agency Center will have primary jurisdiction for premarket review and regulation if it is a combination product. A letter of designation, see 21 CFR 3.2(i), (alternatively referred to as a designation letter) is FDA’s formal response to an RFD and is a binding determination with respect to classification and/or center assignment that may be changed under conditions specified in Section 563 of the FD&C Act and 21 CFR 3.9 in the regulations.” For further information regarding the RFD process, please visit the FDA website, www.fda.gov. Text was taken from FDA’s Guidance for Industry – How to write a Request for Designation (RFD).

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

GrowPros Cannabis Ventures Inc.
Dr. Guy Chamberland
Chief Scientific Officer
(514) 220-9225

GrowPros Cannabis Ventures Inc.
Andre Audet
Executive Chairman
(613) 421-8402

GrowPros MMP
Ryan Brown
President
(613) 421-8402

Medical Marijuana Seems To Reduce Deaths From Pharmaceuticals $MCOA.us $GCI.ca

Posted by AGORACOM-JC at 4:47 PM on Thursday, September 22nd, 2016
  • Columbia University epidemiologist June Kim and her colleagues report that fatally injured drivers are less likely to test positive for opioids in states that allow medical use of marijuana
  • That finding, together with the results of earlier studies, indicates that making marijuana legally available to patients saves lives by reducing their consumption of more dangerous medications.

BY: Jacob Sullum , Contributor

I cover the war on drugs from a conscientious objector’s perspective.

Opinions expressed by Forbes Contributors are their own.

Marijuana jars at the West Coast Collective, a dispensary in Los Angeles (Image: Frederic J. Brown/AFP/Getty Images)

Insys Therapeutics, the Arizona-based pharmaceutical company that recently became the biggest financial supporter of the campaign against marijuana legalization in that state, makes an oral spray that delivers the opioid painkiller fentanyl and plans to market another one that contains dronabinol, a synthetic version of THC. Insys says it gave $500,000 to the main group opposing Arizona’s legalization initiative because the measure “fails to protect the safety of Arizona’s citizens, and particularly its children.” But one needn’t be terribly cynical to surmise that Insys also worries about the impact that legalization might have on its bottom line, since marijuana could compete with its products.

A new study suggests Insys has good reason to worry. In an article published last week by the American Journal of Public Health, Columbia University epidemiologist June Kim and her colleagues report that fatally injured drivers are less likely to test positive for opioids in states that allow medical use of marijuana. That finding, together with the results of earlier studies, indicates that making marijuana legally available to patients saves lives by reducing their consumption of more dangerous medications.

Kim et al. collected data from the Fatality Analysis Reporting System (FARS) for 1999 through 2013, focusing on 18 states that drug-tested at least 80% of drivers who died in crashes. They found that drivers between the ages of 21 and 40 were half as likely to test positive for opioids in states that had implemented medical marijuana laws (MMLs) as in states that had not.

“Among 21-to-40-year-old deceased drivers, crashing in states with an operational MML was associated with lower odds of testing positive for opioids than crashing in MML states before these laws were operational,” the researchers write. “Although we found a significant association only among drivers aged 21 to 40 years, the age specificity of this finding coheres with what we know about MMLs: a minimum age requirement restricts access to medical marijuana for most patients younger than 21 years, and most surveyed medical marijuana patients are younger than 45 years.”

The fact that a driver tested positive for opioids does not necessarily mean the painkillers he took contributed to the crash, so it is not safe to draw any conclusions about medical marijuana’s impact on traffic safety from this study. But the FARS data are an indirect way of measuring the extent of opioid consumption in a given state. Kim et al. note that “severe or chronic pain is among the most common indications cited by medical marijuana patients.” It therefore makes sense that opioid use would decline (or rise less) in states that recognize cannabis as a medicine.

Source: http://www.forbes.com/sites/jacobsullum/2016/09/22/medical-marijuana-seems-to-reduce-deaths-from-pharmaceuticals/#1a6c82b7396e

INTERVIEW: GrowPros (GCI:CSE) Natural Pharmaceuticals Derived From Cannabis and Other Medicinal Plants @growprosmmp $GCI.ca

Posted by AGORACOM-JC at 9:46 AM on Wednesday, September 14th, 2016

Comprised Of Two Divisions

Pharmaceutical Division – PhytoPain Pharma

  • A new subsidiary created June 2, 2016. 80% Ownership
  • Mission is the development and commercialization of botanical based pharmaceuticals
  • A clinical stage drug development company engaged in the development of medication to alleviate symptoms related to: Pain,
    Insomnia, anxiety disorder, in patients suffering from Cancer and other, chronic and terminal diseases

WHY DOCTORS NEED PHARMA MARIJUANA SOLUTIONS

  • A Physician’s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine > A legal, ethical requirement
  • Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer
  • The GrowPros pharmaceutical product development plan would provide the data necessary for physicians to prescribe or recommend our products

Hub On AGORACOM / Watch Interview Now!

AGORACOM Welcomes Marijuana Company of America (MCOA:OTC) At The Forefront Of Hemp Marketing And Distribution $MCOA.us

Posted by AGORACOM-JC at 8:41 AM on Tuesday, September 6th, 2016

15233_mcoa

MCOA: OTC

WHY MCOA?

  • Recently launched Club Harmoneous to provide product distribution services to its members
  • Services provided include product sourcing, processing, product development, marketing, branding, distribution, delivery and customer loyalty through direct sales
  • Recently launched the BudzPlus brand, focused on the medical and recreational marijuana markets
  • In process of launching the HempSmart product line to distribute its hemp-derived products

COMPANY SUMMARY

  • Cannabis and hemp marketing and distribution company that offers premium quality seed-to-solution products for the cannabis and hemp industry and consumers.
  • Delivering all the benefits of cannabis by focusing on ailment-specific, leisure-specific, and health & beauty-specific cannabis product applications.
  • Product sourcing, branding, payment, distribution, and knowledge through a revolutionary architecture to maintain customer loyalty and capture market share.

PRODUCTS

MCOA procures and distributes cannabis and hemp products through a direct sales platform and its Club Harmoneous brand. In legal medical marijuana states, MCOA affiliates will refer consumers to a collective/dispensary. The Company will offer a wide selection of cannabis and hemp derived products. The Company will deliver top quality cannabis products at competitive prices, which will be on the lower end of current market prices.

The Company is also preparing to launch its first proprietary hemp-derived CBD product in Q3 2016. MCOA plans to expand the HempSmart brand and continue to develop and launch new proprietary cannabinoid products on a quarterly basis thereafter.

HempSmart will launch proprietary blended formulations of cannabinoid nutraceutical products for Energy, Sleep, Relaxation, Immunity, Pain, Hair Growth, body care and cosmetic products, food, clothing and more.

THE MARKET

  • Growth in the cannabis industry has been building momentum for more than 5 years. Overwhelming public support is helping fuel exponential growth.
  • Consumers are able to access factual information regarding cannabis, they are less likely to believe the baseless propaganda that is spewed by the opponents of legalization.
  • Dr. Gupta, CNN’s Chief Correspondent, said that he now believes that cannabis does in fact help people.
  • Comments generated significant media coverage around the world. He has since doubled down with a second and third follow up documentaries on cannabis.

Gupta: ‘I am doubling down’ on medical marijuana


Medical marijuana and ‘the entourage effect’

  • Recreational marijuana sales in Colorado and Washington State could top half a billion dollars;
  • The recreational market is expected to continue growing rapidly as more states legalize cannabis, reaching approximately $4.2 billion in 2018;
  • Florida and other unexpected states like Texas could legalize cannabis in 12-18 months, creating scores of new business and investment opportunities;
  • Ancillary industries and companies (those that do not touch the plant) generate hundreds of millions of dollars annually, in additional revenues and will continue to expand alongside cannabis sales;
  • Combined recreational cannabis sales could total an estimated $40-$45 billion, if cannabis is legalized across the United States.

MCOA NEWS CLIPS
12 MONTH STOCK CHART
Chart Image

CLIENT FEATURE: GrowPros (GCI: CSE) Natural Pharmaceuticals Derived From Cannabis and Other Medicinal Plants $GCI.ca

Posted by AGORACOM-JC at 4:37 PM on Wednesday, July 27th, 2016

Growpros_hub_large

Comprised Of Two Divisions

Pharmaceutical Division – PhytoPain Pharma

  • A new subsidiary created June 2, 2016. 80% Ownership
  • Mission is the development and commercialization of botanical based pharmaceuticals
  • A clinical stage drug development company engaged in the development of medication to alleviate symptoms related to: Pain,
    Insomni, anxiety disorder, in patients suffering from Cancer and othe, chronic and terminal diseases

Dr Guy Chamberland, Chief Scientific Officer and Regulatory Affairs

  • Professor of herbal medicine and clinical research at the École d’Enseignement Supérieur de Naturopathie du Québec.
  • 22 years’ experience in the pharmaceutical and natural product industries includes successful development of intellectual property for several botanical drug products

WHY DOCTORS NEED PHARMA MARIJUANA SOLUTIONS

  • A Physician’s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine > A legal, ethical requirement
  • Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer
  • The GrowPros pharmaceutical product development plan would provide the data necessary for physicians to prescribe or recommend our products

PRODUCT PIPELINE

Insomnia Management For Patients With Chronic Pain

  • Licensed a hypnotic drug from Mondias Naturals Inc
  • Management of Insomnia in patients with chronic pain
  • Currently in late stage Phase III clinical testing

PhytoPain To Produce A Combination Product

  • Proprietary combination expected to reach Phase I clinical testing in 2017
  • Will be ready for market in 2017 due to combination with Mondias Naturals product

Pain Management – Inhalation Cannabis Drug Product

  • A prescription drug for management of uncontrolled pain in cancer patients
  • Health Canada will provide guidance during Phase I clinical trial
  • Commencing December 2016. Anticipating 3-5 year product development

A recent discussion with the Quebec College of Physicians confirms that pharmaceutical development of a medical marijuana for inhalation would be well received by the medical community.

OPERATIONS OVERVIEW – MMPR

MMPR Division – Collaboration Agreement

  • March 18, 2016 – Signed agreement with Delta 9 Bio-Tech, a “Licensed Producer”
  • Delta 9 will submit to Health Canada an Amendment to collaborate on GrowPros previous application for facility in Southern Quebec; Amendment submission anticipated by June 30, 2106, Health Canada response anticipated August 30, 2016
  • Key Benefits of Delta 9 Collaboration: Significant process clarity, High probability of success eliminates spec construction risk, Single customer through option to acquire all dried marijuana product for 2 years
  • Key strategic benefit to GrowPros; Controlled production, quality and supply for Pharma Division, Value of license, Wholesale seller vs. retail seller

Hub On AGORACOM /Corporate Profile

PhytoPain Pharma Reports Successful Pre-CTA Consultation With Health Canada for Its Phase I Trial With Cannabis $GCI.ca

Posted by AGORACOM-JC at 8:50 AM on Tuesday, June 28th, 2016

Growpros_hub_large

  • Successful pre-CTA (Clinical Trial Application) consultation with the Therapeutic Products Directorate of Health Canada
  • Proposed Phase I clinical study of smoked cannabis
  • “This is the first step in establishing a key clinical research program aimed at developing the use of inhaled Cannabis as a prescription drug and will provide physicians with evidence on the safety and efficacy of inhaled Cannabis which remains the most commonly preferred form of ingestion by Medical Cannabis Patients,” stated Dr. Chamberland, Chief Scientific Officer and Regulatory Affairs.

OTTAWA, ONTARIO–(June 28, 2016) - PhytoPain Pharma Inc. (“PhytoPain Pharma” or “PPP“), a subsidiary of GrowPros Cannabis Ventures Inc. (“GrowPros” or the “Company“) (CSE:GCI), is pleased to announce a successful pre-CTA (Clinical Trial Application) consultation with the Therapeutic Products Directorate (“TPD“) of Health Canada regarding its proposed Phase I clinical study of smoked cannabis. PhytoPain Pharma submitted for review by the regulators, a pre-CTA information package to brief TPD on the planned clinical study and the investigational drug and its comparator (placebo). Health Canada provided feedback and guidance on the Phase I trial’s study population, placebo material, and neurological and cognitive assessment measures.

PhytoPain Pharma is on track to finalize the clinical protocol and submit the CTA application to TPD. PPP will meet with its Clinical Advisory Board to discuss the guidance from Health Canada and work with a Phase I Clinical Research Organization to implement the recommendations. In addition, PhytoPain Pharma will submit an application for exemption under section 56 of the Controlled Drugs and Substances Act for its planned research on healthy subjects.

“This is the first step in establishing a key clinical research program aimed at developing the use of inhaled Cannabis as a prescription drug and will provide physicians with evidence on the safety and efficacy of inhaled Cannabis which remains the most commonly preferred form of ingestion by Medical Cannabis Patients,” stated Dr. Chamberland, Chief Scientific Officer and Regulatory Affairs.

“I am encouraged at the speed and efficiency displayed by our team in achieving this measurable milestone in the development of our cannabis inhalation drug product. This further validates our belief that, as the regulatory environment surrounding cannabis prohibition continues to evolve, the need for standardised pharmaceutical style products will become the standard in Medicinal Cannabis for physicians, insurers, and regulators. This will position PhytoPain Pharma and GrowPros very favourably as the consumer market continues to develop.”

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

GrowPros Cannabis Ventures Inc.
Ryan Brown
Chief Executive Officer
(613) 421-8402

GrowPros Cannabis Ventures Inc.
Andre Audet
Executive Chairman
(613) 421-8402

GrowPros Cannabis Ventures Inc.
Dr. Guy Chamberland
Chief Scientific Officer and Regulatory Affairs
(514) 220-9225

GrowPros Announces the Acquisition of Laboratoires Holizen Inc. and a $600,000 Non-Brokered Private Placement $GCI.ca

Posted by AGORACOM-JC at 8:40 AM on Wednesday, June 22nd, 2016

Growpros_hub_large

  • Announced the acquisition of the assets of Laboratoires Holizen Inc.
  • Assets will be part of the Company’s new wholly-owned subsidiary Agro-Tek Inc. and will form a new division of GrowPros’ that specializes in the distribution of Natural Health Products and cosmetics
  • Transaction will provide the Company with an established product line and allow GrowPros to rapidly commercialize and distribute new NHPs and cosmetics through Holizen’s strong distribution network

OTTAWA, ONTARIO–(June 22, 2016) - GrowPros Cannabis Ventures Inc. (“GrowPros” or the “Company“) (CSE:GCI) is pleased to announce the acquisition of the assets of Laboratoires Holizen Inc. (“Holizen“) for $450,000. The acquisition will be funded by the $600,000 private placement (see below). These assets will be part of the Company’s new wholly-owned subsidiary Agro-Tek Inc. and will form a new division of GrowPros’ that specializes in the distribution of Natural Health Products (“NHP“) and cosmetics. The transaction will provide the Company with an established product line and allow GrowPros to rapidly commercialize and distribute new NHPs and cosmetics through Holizen’s strong distribution network.

Acquisition Terms:

GrowPros will be required to make a payment of $325,000 on signing the agreement, $50,000 on the 12 month anniversary of the agreement, $50,000 on the 24 month anniversary of the agreement and a final payment of $25,000 on the 36 month anniversary of the agreement. The Agro-Tek team has already commenced applications with different government institutions to access investment funds for developing a strategic growth plan for the sale and distribution of Holizen products to the rest of Canada and the United States in the next year.

Asset Highlight

GrowPros has acquired Holizen’s existing customer base, inventory and natural product registration numbers.

The acquisition of Holizen’s assets by GrowPros will not change Holizen’s daily activities. The current President of Holizen, Mrs. Francine St-Sauveur, and all of the company’s employees and consultants will be retained by GrowPros. Mrs. St-Sauveur will assume the role and responsibility of the Chief Operating Officer of Agro-Tek. In her new role, Mrs. St-Sauveur will be responsible for day-to-day operations and client relations including the company’s network of retail stores. Mr. André Rancourt was appointed as Chief Executive Officer of Agro-Tek and will take over the management of all of its divisions and partnerships. “The Board of Directors and I are delighted that Mr. Rancourt has agreed to accept this responsibility,” said André Audet, Chairman. “He is someone with tremendous experience in the NHP retail market, his unquestioned work ethic, and integrity will prove to be of great value to the growth of the Company”. Mr. Rancourt has worked in the food and NHP market for over 20 years and has established an extensive network of contacts. André will be responsible for the overall commercial strategy of Agro-Tek, licencing of innovative technologies, and future acquisitions to expand the Company’s product lines and distribution capabilities. Holizen products are currently distributed in over 200 Natural health stores in Quebec. The company plans to launch an aggressive expansion to try and grow its market share of the 11.3 Billion dollar FFNHP (functional foods and Natural Health Products) market Place *stats Canada.

Holizen was created in 2002 and has been producing and distributing high quality NHP and cosmetic products. In addition to its NHP line, Mrs. St-Sauveur created alliances with several highly reputable European laboratories to offer Egyptian spagyria products, certified organic skincare products, and a line of silicon-based supplements and gels. “Holizen owes its fame to the absolute quality and efficiency of its products, a long and established network of clients, and the dedication of its employees to serve clients with respect and promptness,” stated Mrs. St-Sauveur. “The acquisition by GrowPros will allow the company to rapidly expand the distribution of its product lines across all of North America and continue to offer its clients innovative, effective, and high quality NHP and cosmetic products.”

Summary

The acquisition and recent creation of the multiple subsidiaries will provide GrowPros with a diversified portfolio of companies operating in independent yet related fields. PhytoPain Pharma Inc. will focus on pharmaceutical development, Agro-Tek will focus on retail product distribution and Grow Pros MMP will focus on cultivation and production of medicinal plants including Cannabis for which the company requires an approval under the Marijuana for Medical Purposes Regulation (“MMPR“).

“This platform should allow GrowPros to evolve into a fully integrated Pharmaceutical and Natural Health product development, production, and distribution company. This strategy provides multiple revenue streams across various industry segments and sub segments and insulates the company from the uncertainty that results from solely focusing on an MMPR application,” stated Ryan Brown, GrowPros CEO.

Financial Terms:

The Company also announces a non-brokered private placement of 12,000,000 units at a price of $0.05 per unit for aggregate gross proceeds of up to $600,000. Each unit will consist of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $0.07 for a period of 12 months following the closing date.

In connection with the private placement, the Company may pay a cash finder’s fee equal to 8% of the gross proceeds raised and may issue non-transferable finder’s warrants equal to 8% of the number of common shares issued under the private placement. Each finder’s warrant will entitle the holder to purchase one common share of the Company at a price of $0.07 per share for a period of 12 months following the closing of the private placement.

The securities issued pursuant to the private placement will be subject to a four-month hold period from the closing date. The Company may pay a commission in connection with the private placement, subject to compliance with the policies of the Exchange. Completion of the private placement and the payment of any commissions remain subject to the receipt of all necessary regulatory approvals, including the approval of the Exchange.

The proceeds of the private placement will be used to fund the acquisition of the assets of Holizen as well as general working capital.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Contact Information

  • GrowPros Cannabis Ventures Inc.
    Ryan Brown
    Chief Executive Officer
    (613) 421-8402GrowPros Cannabis Ventures Inc.
    Andre Audet
    Executive Chairman
    (613) 421-8402GrowPros Cannabis Ventures Inc.
    Dr. Guy Chamberland
    Chief Scientific Officer and Regulatory Affairs
    (514) 220-9225

AGORACOM Welcomes GrowPros Cannabis Ventures (GCI: CSE) Developing Natural Pharmaceuticals Derived From Cannabis and Other Medicinal Plants $GCI.ca

Posted by AGORACOM-JC at 4:58 PM on Monday, June 20th, 2016

Growpros_hub_large

GCI:CSE

Pharmaceutical Division – PhytoPain Pharma

  • A new subsidiary created June 2, 2016. 80% Ownership
  • Mission is the development and commercialization of botanical based pharmaceuticals
  • A clinical stage drug development company engaged in the development of medication to alleviate symptoms related to: Pain, Insomnia, anxiety disorder, in patients suffering from Cancer and other, chronic and terminal diseases

Dr Guy Chamberland, Chief Scientific Officer and Regulatory Affairs

  • Professor of herbal medicine and clinical research at the École d’Enseignement Supérieur de Naturopathie du Québec.
  • 22 years’ experience in the pharmaceutical and natural product industries includes successful development of intellectual property for several botanical drug products

WHY DOCTORS NEED PHARMA MARIJUANA SOLUTIONS

  • A Physician’s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine > A legal, ethical requirement
  • Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer
  • The GrowPros pharmaceutical product development plan would provide the data necessary for physicians to prescribe or recommend our products

PRODUCT PIPELINE

Insomnia Management For Patients With Chronic Pain

  • Licensed a hypnotic drug from Mondias Naturals Inc
  • Management of Insomnia in patients with chronic pain
  • Currently in late stage Phase III clinical testing

PhytoPain To Produce A Combination Product

  • Proprietary combination expected to reach Phase I clinical testing in 2017
  • Will be ready for market in 2017 due to combination with Mondias Naturals product

Pain Management – Inhalation Cannabis Drug Product

  • A prescription drug for management of uncontrolled pain in cancer patients
  • Health Canada will provide guidance during Phase I clinical trial
  • Commencing December 2016. Anticipating 3-5 year product development

A recent discussion with the Quebec College of Physicians confirms that pharmaceutical development of a medical marijuana for inhalation would be well received by the medical community.

OPERATIONS OVERVIEW – MMPR

MMPR Division – Collaboration Agreement

  • March 18, 2016 – Signed agreement with Delta 9 Bio-Tech, a “Licensed Producer”
  • Delta 9 will submit to Health Canada an Amendment to collaborate on GrowPros previous application for facility in Southern Quebec; Amendment submission anticipated by June 30, 2106, Health Canada response anticipated August 30, 2016
  • Key Benefits of Delta 9 Collaboration: Significant process clarity, High probability of success eliminates spec construction risk, Single customer through option to acquire all dried marijuana product for 2 years
  • Key strategic benefit to GrowPros; Controlled production, quality and supply for Pharma Division, Value of license, Wholesale seller vs. retail seller

Hub On AGORACOM / Corporate Profile / Read Release

PhytoPain Pharma Files Clinical Trial Application (CTA) for a Topical Product for the Treatment of Chemotherapy-Induced Neuropathic Pain $GCI.ca

Posted by AGORACOM-JC at 8:54 AM on Wednesday, June 15th, 2016

Growpros

  • Announced that it has filed a Clinical Trial Application (CTA) with Health Canada for PhytoPain Topical Gel Relief (PPTGR), a locally administered therapeutic for the treatment of chemotherapy-induced neuropathic pain (CINP)
  • Upon approval of the CTA, the Company plans to initiate a double-blind, randomized, cross-over, placebo-controlled clinical study with PPTGR in late 2016 and expects to report initial clinical data from the trial in late 2017

OTTAWA, ONTARIO–(June 15, 2016) - PhytoPain Pharma (PPP) Inc., a subsidiary of GrowPros Cannabis Ventures Inc. (“GrowPros” or the “Company” or “GCI“) (CSE:GCI), today announced that it has filed a Clinical Trial Application (CTA) with Health Canada for PhytoPain Topical Gel Relief (PPTGR), a locally administered therapeutic for the treatment of chemotherapy-induced neuropathic pain (CINP). Upon approval of the CTA, the Company plans to initiate a double-blind, randomized, cross-over, placebo-controlled clinical study with PPTGR in late 2016 and expects to report initial clinical data from the trial in late 2017.

CINP is a common adverse effect of cancer therapy and a frequent reason why cancer patients stop their treatment early. For some patients, the severity of the symptoms can be reduced by lowering the dose of chemotherapy or temporarily stopping it. In other patients, the symptoms of CINP may last for months or years after the cancer therapy has stopped. CINP symptoms are managed using the same analgesics used to manage other types of neuropathic pain. Some of these analgesics also cause intolerable side effects in patients. The use of a topical counterirritant may help reduce the symptoms of CINP and avoid exposing some patients to oral neuropathic pain analgesics.

According to Dr. Guy Chamberland, the Company’s Chief Scientific Officer, “PPP is developing this topical product to provide cancer patients a safer, natural and more tolerable alternative in the management of CINP”. The development of the PPTGR product is in line with PPP’s strategy to bring an integrative medical approach for cancer patients suffering from pain. “The demonstration of the safety and efficacy of botanical drugs including cannabis for pain management is a critical step in the development of an evidence-based approach to integrative medical care. PPP intends on working with physicians to demonstrate that PPTGR can be safely used as an adjunct to inhalation and oral medical marijuana for the reduction of pain in cancer patients. Physicians need additional drugs that can help reduce the amount of narcotics required to manage pain while minimizing the risk of psycho active effects or tolerance to opioids, cannabis, and other narcotics commonly prescribed to patients. The intention is to develop PPTGR, and other botanical-based drugs, as adjuncts to the standard of care,” stated Dr. Chamberland.

PPTGR is a counterirritant topical gel that conforms to the Natural and Non-prescription Health Products Directorate (NNHPD) monograph. However, the intended use of counterirritant products under the NNHPD monograph does not include the temporary relief of CINP. PPP is launching a clinical trial to demonstrate the safety and efficacy of PPTGR in cancer patients with CINP and work with medical oncologists to integrate the use of PPTGR in the management of CINP.

International research indicates that 60% of patients undergoing chemotherapy will suffer from varying degrees of CINP during their treatment. PPP believes it can demonstrate increased symptom alleviation using natural based agents and mixtures as opposed to the synthetic alternatives. “PPP was created to conduct cannabinoid and medicinal plant based research with the goal of developing over-the-counter products for consumers and prescription drug products for physicians that can be distributed through the existing pharmaceutical infrastructure. This submission is the first step in the growth of our vision,” commented CEO Ryan Brown.

CINP Market Size and comparison products

MARKET STATISTICS:

There were an estimated 15.2 million cancer cases globally in 2014 according to the International Agency for Research on Cancer (IARC) with projections of 17.1 million cases in 2020. Roughly 25%-30% of cancer patients receive chemotherapy, and of those patients, 70%-80% experience a form of CINP. The global CINP market saw estimated revenue of $1.3 billion in 2014 with a projected 5.7% compounded annual growth rate through 2020 as cancer rates climb with growing, aged populations. Of the products available Oral delivery drug of dronabinol which is comprised of synthetic cannabinoids had sales of $110M in 2014. Similar to other mainly orally administered cannabinoids, results in relatively low bioavailability, coupled with irregular pharmacokinetics secondary to absorption variability and first-pass metabolism by the liver, complicated by the need for multiple dosages per day. In addition, many patients report nausea and/or vomiting as a side-effect related to the drug. (NEMUS BIO SCIENCE)

Many studies have concluded that natural cannabinoids offer a safer, more effective solution than their synthetic counterparts. A recent article entitled Comparison of Outcome Expectancies for Synthetic Cannabinoids and Botanical Marijuana, from The American Journal of Drug and Alcohol Abuse, concluded that given growing public acceptance of recreational and medical marijuana, coupled with negative perceptions and increasing regulation of synthetic cannabinoid compounds, botanical marijuana is likely to remain more available and more popular than synthetic cannabinoids.

PPP is proud to position itself as a leader in the development of natural pharmaceuticals derived Cannabis and other medicinal plants,” commented CEO Ryan Brown.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

GrowPros Cannabis Ventures Inc.
Ryan Brown
Chief Executive Officer
(613) 421-8402

GrowPros Cannabis Ventures Inc.
Andre Audet
Executive Chairman
(613) 421-8402

GrowPros Cannabis Ventures Inc.
Dr. Guy Chamberland
Chief Scientific Officer and Regulatory Affairs
(514) 220-9225